Patents by Inventor Greg Nitzel
Greg Nitzel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9101561Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2ORF2 protein, and immunogenic compositions comprising PCV2ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2ORF2 protein, or an immunogenic composition comprising PCV2ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.Type: GrantFiled: January 9, 2012Date of Patent: August 11, 2015Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
-
Publication number: 20150190497Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: ApplicationFiled: March 18, 2015Publication date: July 9, 2015Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 9011868Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: May 12, 2011Date of Patent: April 21, 2015Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20130101621Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: ApplicationFiled: December 27, 2012Publication date: April 25, 2013Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20120107348Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein.Type: ApplicationFiled: January 9, 2012Publication date: May 3, 2012Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
-
Patent number: 8119143Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.Type: GrantFiled: June 11, 2008Date of Patent: February 21, 2012Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
-
Publication number: 20110274710Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: ApplicationFiled: July 25, 2011Publication date: November 10, 2011Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 8025888Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: GrantFiled: June 12, 2008Date of Patent: September 27, 2011Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20110217327Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: May 12, 2011Publication date: September 8, 2011Applicant: Boehringer Ingelheim Vetmedica, IncInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 7968285Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: June 11, 2008Date of Patent: June 28, 2011Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 7910306Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: GrantFiled: June 12, 2008Date of Patent: March 22, 2011Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 7838214Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: June 11, 2008Date of Patent: November 23, 2010Assignee: Boehringer Ingelheim Vetmedical, Inc.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 7838213Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: June 11, 2008Date of Patent: November 23, 2010Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 7833707Abstract: An improved method for recovering the protein expressed by open reading frame 2 from PCV2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: GrantFiled: January 13, 2005Date of Patent: November 16, 2010Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 7829273Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: June 11, 2008Date of Patent: November 9, 2010Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 7829101Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: GrantFiled: June 12, 2008Date of Patent: November 9, 2010Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Patent number: 7700285Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: GrantFiled: December 29, 2005Date of Patent: April 20, 2010Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20090092636Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein.Type: ApplicationFiled: June 11, 2008Publication date: April 9, 2009Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
-
Publication number: 20090042245Abstract: An improved method for recovering the protein expressed by open reading frame 2 from PCV2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: ApplicationFiled: January 13, 2005Publication date: February 12, 2009Inventors: Mark Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20090022750Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: ApplicationFiled: June 12, 2008Publication date: January 22, 2009Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer